Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG
Open Access
- 1 October 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 46 (4) , 565-570
- https://doi.org/10.1093/jac/46.4.565
Abstract
The in vitro activity of rifapentine and its metabolite, 25-O-desacetylrifapentine, as compared with that of rifampicin and rifabutin, was determined against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. MICs were determined radiometrically and by the 1% proportional method using Middlebrook 7H11 agar. The bactericidal effect of the drugs was determined in parallel at selected concentrations. For drugsusceptible isolates of M. tuberculosis, the Bactec MICs of rifapentine and 25-O-desacetylrifapentine were 0.03–0.06 mg/L and 0.125–0.25 mg/L, respectively. Similar MICs were obtained for M. africanum (0.03–0.125 and 0.125–0.50 mg/L, respectively), and M. bovis (0.063–0.25 and 0.125–1.0 mg/L, respectively), but MICs were considerably lower for M. bovis BCG (0.008–0.063 mg/L for rifapentine and 0.016–0.125 mg/L for its metabolite). In general, MICs determined using 7H11 agar medium were usually one or two dilutions higher than those obtained using Bactec broth. When compared with rifampicin and rifabutin, the inhibitory activity of rifapentine for drug-susceptible isolates was roughly equal to that of rifabutin, and the inhibitory activity of 25-O-desacetylrifapentine was comparable to that of rifampicin; however, rifapentine was somewhat more bactericidal than rifabutin at equal concentrations. Clinical isolates of M. tuberculosis with a high degree of resistance to rifampicin (MIC ≥ 32 mg/L) were also highly resistant to rifabutin, rifapentine and 25-O-desacetylrifapentine, although the MICs of rifabutin in this case were somewhat lower than the MICs of rifapentine.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacokinetics of Rifapentine in Subjects Seropositive for the Human Immunodeficiency Virus: a Phase I StudyAntimicrobial Agents and Chemotherapy, 1999
- Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalisJournal of Antimicrobial Chemotherapy, 1999
- Once-weekly Rifapentine-containing Regimens for Treatment of Tuberculosis in MiceAmerican Journal of Respiratory and Critical Care Medicine, 1998
- RifapentineDrugs, 1998
- Current problems with tuberculosis treatmentResearch in Microbiology, 1996
- Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis.American Journal of Respiratory and Critical Care Medicine, 1996
- Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophagesAntimicrobial Agents and Chemotherapy, 1995
- In vitro activity of roxithromycin against the Mycobacterium tuberculosis complexAntimicrobial Agents and Chemotherapy, 1995
- RifabutinDrugs, 1994
- Emergence of multiple-drug-resistant tuberculosis: fundamental and applied research aspects, global issues and current strategiesResearch in Microbiology, 1993